Tabula Rasa HealthCare Inc (NASDAQ:TRHC) has earned a consensus rating of “Buy” from the fourteen research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $82.27.

A number of research firms have commented on TRHC. Robert W. Baird upped their price target on Tabula Rasa HealthCare from $70.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 19th. Citigroup upped their price target on Tabula Rasa HealthCare to $100.00 and gave the stock a “buy” rating in a research note on Thursday, October 11th. Zacks Investment Research upgraded Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Thursday, December 13th. BidaskClub upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research note on Tuesday, November 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $99.00 price target on shares of Tabula Rasa HealthCare in a research note on Tuesday, November 6th.

TRHC opened at $64.94 on Friday. Tabula Rasa HealthCare has a one year low of $28.55 and a one year high of $91.16. The company has a market capitalization of $1.25 billion, a P/E ratio of -1,623.50, a price-to-earnings-growth ratio of 3.89 and a beta of 2.45. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.46 and a current ratio of 0.49.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.07. Tabula Rasa HealthCare had a positive return on equity of 7.63% and a negative net margin of 13.49%. The firm had revenue of $54.42 million for the quarter, compared to analysts’ expectations of $52.87 million. During the same period in the prior year, the firm posted $0.08 earnings per share. The firm’s quarterly revenue was up 66.3% on a year-over-year basis. As a group, analysts anticipate that Tabula Rasa HealthCare will post 0.42 EPS for the current year.

In other news, CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction on Monday, January 7th. The stock was sold at an average price of $63.06, for a total transaction of $504,480.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Samira Beckwith sold 1,733 shares of the company’s stock in a transaction on Wednesday, December 12th. The stock was sold at an average price of $75.76, for a total value of $131,292.08. The disclosure for this sale can be found here. Insiders have sold 55,790 shares of company stock worth $3,761,171 over the last 90 days. 14.00% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of TRHC. BlackRock Inc. increased its position in shares of Tabula Rasa HealthCare by 29.7% during the second quarter. BlackRock Inc. now owns 2,119,507 shares of the company’s stock worth $135,288,000 after acquiring an additional 484,979 shares during the period. NN Investment Partners Holdings N.V. increased its holdings in Tabula Rasa HealthCare by 45.2% in the third quarter. NN Investment Partners Holdings N.V. now owns 669,800 shares of the company’s stock valued at $54,380,000 after buying an additional 208,604 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Tabula Rasa HealthCare by 673.0% in the third quarter. Wells Fargo & Company MN now owns 187,511 shares of the company’s stock valued at $15,224,000 after buying an additional 163,255 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in Tabula Rasa HealthCare in the third quarter valued at $6,933,000. Finally, Northern Trust Corp increased its holdings in Tabula Rasa HealthCare by 52.3% in the second quarter. Northern Trust Corp now owns 227,503 shares of the company’s stock valued at $14,522,000 after buying an additional 78,112 shares during the last quarter. 74.87% of the stock is currently owned by institutional investors and hedge funds.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

See Also: LIBOR

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.